Zenas BioPharma (ZBIO) Invested Capital (2023 - 2026)

Zenas BioPharma's Invested Capital history runs 4 years deep, the most recent figure standing at $335.8 million for Q1 2026.

• In Q1 2026, Invested Capital rose 18.12% year-over-year to $335.8 million; the TTM figure through Mar 2026 stood at $335.8 million (up 18.12% YoY), while the FY2025 annual figure was $242.1 million, down 22.5% from the prior year.
• Invested Capital was $335.8 million for Q1 2026 at Zenas BioPharma, up from $242.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $359.4 million in Q3 2024 to a low of -$288.8 million in Q2 2024.
• Historically, Invested Capital has averaged $91.0 million across 4 years, with a median of $239.6 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Invested Capital jumped 277.73% in 2024, then plunged 45.35% in 2025.
• A 4-year view of Invested Capital shows it stood at -$225.7 million in 2023, then surged by 238.43% to $312.5 million in 2024, then fell by 22.5% to $242.1 million in 2025, then jumped by 38.69% to $335.8 million in 2026.
• The last three Invested Capital figures came in at $335.8 million (Q1 2026), $242.1 million (Q4 2025), and $196.4 million (Q3 2025), per Business Quant data.